Publications by authors named "Anthony Sebba"

Claim this Profile
R
Real-World Treatment Patterns, Clinical Outcomes, and Symptom Burden in Patients With Psoriatic Arthritis Prescribed Ixekizumab in the United States.
Sherry Rohekar, Aisha Vadhariya, Sarah Ross, William Malatestinic, Boris Janos, Anthony Sebba

ACR Open Rheumatol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry.
Anthony Sebba, Clifton O Bingham, Vivian P Bykerk, Stefano Fiore, Kerri Ford

Clin Rheumatol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab.
Ernest Choy, Vivian Bykerk, Yvonne C Lee, Hubert van Hoogstraten, Kerri Ford, Anthony Sebba

Rheumatology (Oxford)· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pain: A Review of Interleukin-6 and Its Roles in the Pain of Rheumatoid Arthritis.
Anthony Sebba

Open Access Rheumatol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Jak/STAT pathway: A focus on pain in rheumatoid arthritis.
Lee S Simon, Peter C Taylor, Ernest H Choy, Anthony Sebba, Amanda Quebe

Semin Arthritis Rheum· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study.
Josef S Smolen, Anthony Sebba, Eric M Ruderman, Hendrik Schulze-Koops, Christophe Sapin

Rheumatol Ther· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.
Robert J Moots, Anthony Sebba, William Rigby, Andrew Ostor, Benjamin Porter-Brown

Rheumatology (Oxford)· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year Efficacy and Safety of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Methotrexate- and Biologic-naive or Free of Methotrexate for 6 Months: the AMBITION Study.
Graeme Jones, Thomas Wallace, Matthew J McIntosh, Laura Brockwell, Juan J Gómez-Reino, Anthony Sebba

J Rheumatol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab.
Andrea Rubbert-Roth, Anthony Sebba, Laura Brockwell, Ariella Kelman, Benjamin Porter-Brown

RMD Open· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis.
Paul Emery, Anthony Sebba, Tom W J Huizinga

Ann Rheum Dis· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.
Mark C Genovese, Andrea Rubbert-Roth, Josef S Smolen, Joel Kremer, Majed Khraishi, Anthony Sebba

J Rheumatol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study.
Rieke Alten, Juan Gomez-Reino, Patrick Durez, Andre Beaulieu, Anthony Sebba

BMC Musculoskelet Disord· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
S Aubrey Stoch, Kenneth G Saag, Maria Greenwald, Anthony I Sebba, Stanley Cohen

J Rheumatol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment.
Nelson B Watts, Paul D Miller, Lynn A Kohlmeier, Anthony Sebba, Peiqi Chen

J Bone Miner Res· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates.
Sherri-Ann M Burnett-Bowie, Kenneth Saag, Anthony Sebba, Anne E de Papp, Erluo Chen

J Clin Endocrinol Metab· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis.
Anthony I Sebba, Ronald D Emkey, Joseph D Kohles, Philip N Sambrook

Bone· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osteoporosis: how long should we treat?
Anthony Sebba

Curr Opin Endocrinol Diabetes Obes· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tocilizumab: the first interleukin-6-receptor inhibitor.
Anthony Sebba

Am J Health Syst Pharm· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of etoricoxib in the treatment of osteoarthritis.
Anthony Sebba

Expert Rev Clin Pharmacol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
Anthony I Sebba

Clin Ther· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.
Sydney Bonnick, Kenneth G Saag, Douglas P Kiel, Michael McClung, Marc Hochberg, Anthony Sebba

J Clin Endocrinol Metab· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis.
Paula J Rackoff, Anthony Sebba

Treat Endocrinol· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
Anthony I Sebba, Sydney Lou Bonnick, Risa Kagan, Desmond E Thompson, Carol S Skalky

Curr Med Res Opin· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis.
Tino Munster, John P Gibbs, Danny Shen, Bruce A Baethge, Gary R Botstein, Anthony I Sebba

Arthritis Rheum· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis